Last reviewed · How we verify
Inmazeb (MAFTIVIMAB)
Inmazeb works by binding to and neutralizing the Ebola virus.
At a glance
| Generic name | MAFTIVIMAB |
|---|---|
| Sponsor | Regeneron |
| Modality | Monoclonal antibody |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2020 |
| Annual revenue | 76 |
Mechanism of action
INMAZEB is an antiviral drug combination of three recombinant human IgG1 monoclonal antibodies (atoltivimab, maftivimab, and odesivimab) that inhibit Zaire ebolavirus [see Microbiology (12.4) ].
Approved indications
- Ebola virus disease
Common side effects
- Pyrexia
- Chills
- Tachycardia
- Tachypnea
- Vomiting
- Hypotension
- Diarrhea
- Hypoxia
- Sodium, high
- Sodium, low
- Potassium, high
- Potassium, low
Key clinical trials
- EBOla Post-Exposure Prophylaxis (PHASE3)
- Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers (PHASE2)
- R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
- Investigational Therapeutics for the Treatment of People With Ebola Virus Disease (PHASE2,PHASE3)
- Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |